Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 9/20 | 0.47 |
| ▸ | IDH1 | O75874 | 9/20 | 0.41 |
| ▸ | IDH2 | P48735 | 4/20 | 0.41 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20270981 | 1.00 | ACACB (0.47) | ACACBIDH1IDH2TEAD1 | |
| SCHEMBL21799146 | 1.00 | ACACB (0.47) | ACACBIDH1IDH2TEAD1 | |
| SCHEMBL20289697 | 0.87 | ALDH1A1 (0.47) | ACACBIDH1IDH2 | |
| SCHEMBL22186807 | 0.87 | ALDH1A1 (0.47) | ACACBIDH1IDH2 | |
| SCHEMBL19700717 | 0.87 | ALDH1A1 (0.47) | ACACBIDH1IDH2 | |
| SCHEMBL21378401 | 0.86 | ACACB (0.41) | ACACBIDH1IDH2 | |
| SCHEMBL21378399 | 0.86 | ACACB (0.41) | ACACBIDH1IDH2 | |
| SCHEMBL21799111 | 0.85 | ACACB (0.41) | ACACBIDH1IDH2TEAD1 | |
| SCHEMBL21799110 | 0.85 | ACACB (0.41) | ACACBIDH1IDH2TEAD1 | |
| SCHEMBL21799062 | 0.82 | ACACB (0.43) | ACACBIDH1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208978-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-4356914-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2024-04-24 | — | — | EP | disclosed |
| US-20230174550-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-06-08 | — | — | US | disclosed |
| US-11649247-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | ELI LILLY AND COMPANY (US) | 2023-05-16 | — | — | US | disclosed |
| US-11629156-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | ELI LILLY AND COMPANY (US) | 2023-04-18 | — | — | US | disclosed |
| EP-3763717-B1 | PYRIDO[4,3-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | LILLY CO ELI (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20210230185-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | ELI LILLY AND COMPANY | 2021-07-29 | — | — | US | disclosed |
| US-20210206780-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | ELI LILLY AND COMPANY | 2021-07-08 | — | — | US | disclosed |
| US-11001596-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | ELI LILLY AND COMPANY (US) | 2021-05-11 | — | — | US | disclosed |
| EP-3763717-A1 | PYRIDO[4,3-D][1,3]OXAZIN-2-ONE AND PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | ELI LILLY AND CO. (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3555105-B1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | LILLY CO ELI (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3464281-B1 | MUTANT IDH1 INHIBITORS | LILLY CO ELI (US) | 2020-07-08 | — | — | EP | disclosed |
| US-10696665-B2 | Mutant IDH1 inhibitors | ELI LILLY AND COMPANY (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200079791-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | ELI LILLY AND COMPANY | 2020-03-12 | — | — | US | disclosed |
| EP-3555105-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | Eli Lilly and Company (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190292175-A1 | MUTANT IDH1 INHIBITORS | ELI LILLY AND COMPANY | 2019-09-26 | — | — | US | disclosed |
| WO-2018111707-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649247-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | IDH2, IDH1, IDH3B | ACACB 996/4885IDH1 2/4885IDH2 1/4885 |
| US-20210230185-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | IDH2, IDH1, IDH3B | ACACB 996/4885IDH1 2/4885IDH2 1/4885 |
| US-10696665-B2 | Mutant IDH1 inhibitors | IDH1, IDH3B, IDH3A | ACACB 400/4885IDH1 1/4885IDH2 4/4885 |
| US-20210206780-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | IDH2, IDH1, IDH3B | ACACB 996/4885IDH1 2/4885IDH2 1/4885 |
| US-20190292175-A1 | MUTANT IDH1 INHIBITORS | IDH1, IDH3B, IDH3A | ACACB 400/4885IDH1 1/4885IDH2 4/4885 |
| US-11629156-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | IDH2, IDH1, IDH3B | ACACB 996/4885IDH1 2/4885IDH2 1/4885 |
| US-20230174550-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | IDH1, IDH3A, IDH3B | ACACB 1796/4885IDH1 1/4885IDH2 4/4885 |
| US-20200079791-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | IDH2, IDH1, IDH3B | ACACB 996/4885IDH1 2/4885IDH2 1/4885 |
| US-11001596-B2 | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors | IDH2, IDH1, IDH3B | ACACB 996/4885IDH1 2/4885IDH2 1/4885 |
| US-20240208978-A1 | IDH MUTANT INHIBITOR AND USE THEREOF | IDH1, IDH3A, IDH3B | ACACB 1736/4885IDH1 1/4885IDH2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.